{
    "id": 7204,
    "fullName": "FIP1L1 - PDGFRA",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FIP1L1-PDGFRA results from of FIP1L1 and PDGFRA, creating a fuision protein with constitutive tyrosine kinase activity and the ability to transform cells in culture (PMID: 12660384, PMID: 12781364, PMID: 16030188).",
            "references": [
                {
                    "id": 15308,
                    "pubMedId": 16030188,
                    "title": "The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16030188"
                },
                {
                    "id": 2987,
                    "pubMedId": 12781364,
                    "title": "PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR\u03b1-induced myeloproliferative disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12781364"
                },
                {
                    "id": 2988,
                    "pubMedId": 12660384,
                    "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12660384"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 81608,
        "geneSymbol": "FIP1L1",
        "terms": [
            "FIP1L1",
            "FIP1",
            "hFip1",
            "Rhe"
        ]
    },
    "variant": "FIP1L1 - PDGFRA",
    "createDate": "06/08/2015",
    "updateDate": "06/10/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5156,
                "geneSymbol": "PDGFRA",
                "terms": [
                    "PDGFRA",
                    "CD140A",
                    "PDGFR-2",
                    "PDGFR2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11472,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Dovitinib (TKI258) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11473,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Iressa (gefitinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Tarceva (erlotinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17278,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Nexavar (sorafenib) in culture, demonstrating decreased cell viability (PMID: 16645167).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14731,
                    "pubMedId": 16645167,
                    "title": "Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16645167"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11470,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Nexavar (sorafenib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA T674I in the context of the FIP1L1-PDGFRA fusion demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 16030188).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15308,
                    "pubMedId": 16030188,
                    "title": "The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16030188"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2360,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, an acute myeloid leukemia patient harboring FIP1L1-PDGFRA and a PDGFRA T674I secondary mutation demonstrated resistance to Gleevec (imatinib) (PMID: 18843283, PMID: 12660384).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2988,
                    "pubMedId": 12660384,
                    "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12660384"
                },
                {
                    "id": 2990,
                    "pubMedId": 18843283,
                    "title": "Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18843283"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Votrient (pazopanib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Sutent (sunitinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8005,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited Pdgfra signaling and viability in leukemia cells harboring FIP1L1-PDGFRA in culture (PMID: 21482694).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3255,
                    "pubMedId": 21482694,
                    "title": "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21482694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of hypereosinophilic leukemia cells harboring FIP1L1-PDGFRA in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17405,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, Gleevec (imatinib) resulted in complete response in 35.7% (5/14) and partial response in 7.1% (1/14) of patients with hypereosinophilic syndrome, and responses were demonstrated in the 3 patients of 7 screened that harbored FIP1L1-PDGFRA, while none of the 4 patients that were negative for FIP1L1-PDGFRA demonstrated responses (PMID: 18451237).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6183,
                    "pubMedId": 18451237,
                    "title": "Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18451237"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4388,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 100% (16/16) of patients with chronic eosinophilic leukemia harboring FIP1L1-PDGFRA demonstrated a complete hematological remission after 3 months, and 75% (12/16) demonstrated a complete molecular remission by 6 months following treatment with Gleevec (imatinib) (PMID: 18950453).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4510,
                    "pubMedId": 18950453,
                    "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18950453"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA demonstrated sensitivity to growth inhibition by Tasigna (nilotinib) in culture (PMID: 16030188).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15308,
                    "pubMedId": 16030188,
                    "title": "The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16030188"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7416,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing FIP1L1-PDGFRA in culture and prolonged survival in xenograft models (PMID: 21224473).",
            "molecularProfile": {
                "id": 7080,
                "profileName": "FIP1L1 - PDGFRA"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA D842V in the context of the FIP1L1-PDGFRA fusion demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 24407160).",
            "molecularProfile": {
                "id": 26541,
                "profileName": "FIP1L1 - PDGFRA PDGFRA D842V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6789,
                    "pubMedId": 24407160,
                    "title": "Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24407160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8931,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA D842V in the context of the FIP1L1-PDGFRA fusion demonstrated resistance to growth inhibition by Sutent (sunitinib) in culture (PMID: 24407160).",
            "molecularProfile": {
                "id": 26541,
                "profileName": "FIP1L1 - PDGFRA PDGFRA D842V"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6789,
                    "pubMedId": 24407160,
                    "title": "Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24407160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA D842V in the context of the FIP1L1-PDGFRA fusion demonstrated resistance to growth inhibition by Masitinib (AB1010) in culture (PMID: 24407160).",
            "molecularProfile": {
                "id": 26541,
                "profileName": "FIP1L1 - PDGFRA PDGFRA D842V"
            },
            "therapy": {
                "id": 804,
                "therapyName": "Masitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6789,
                    "pubMedId": 24407160,
                    "title": "Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24407160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8930,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells expressing PDGFRA D842V in the context of the FIP1L1-PDGFRA fusion in culture (PMID: 24407160).",
            "molecularProfile": {
                "id": 26541,
                "profileName": "FIP1L1 - PDGFRA PDGFRA D842V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6789,
                    "pubMedId": 24407160,
                    "title": "Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24407160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18738,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in rapid clinical improvement and sustained response in a patient with clonal eosinophilia harboring an FIP1L1-PDGFRA fusion and PDGFRA P6L, with the mutation rate of FIP1L1-PDGFRA decreased from 3.8% to undetectable and PDGFRA P6L decreased from 57.9% to 38.1% after 1 year of treatment (PMID: 30359545).",
            "molecularProfile": {
                "id": 33555,
                "profileName": "FIP1L1 - PDGFRA PDGFRA P6L"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16326,
                    "pubMedId": 30359545,
                    "title": "Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30359545"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7079,
            "profileName": "FIP1L1 - PDGFRA PDGFRA T674I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7080,
            "profileName": "FIP1L1 - PDGFRA",
            "profileTreatmentApproaches": [
                {
                    "id": 7719,
                    "name": "Imatinib",
                    "profileName": "FIP1L1 - PDGFRA"
                }
            ]
        },
        {
            "id": 26541,
            "profileName": "FIP1L1 - PDGFRA PDGFRA D842V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33555,
            "profileName": "FIP1L1 - PDGFRA PDGFRA P6L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}